Do you want to read an article? Please log in or register.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis
United European Gastroenterol J.
Ochsenkühn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F
doi: 10.1177/2050640619895361.
Inflammatory Bowel Disease
Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis
J Crohns Colitis.
Pouillon L, Rousseau H, Busby-Venner H, De Carvalho Bittencourt M, Choukour M, Gauchotte G, Zallot C, Danese S, Baumann C, Peyrin-Biroulet L
doi: 10.1093/ecco-jcc/jjz029.
Inflammatory Bowel Disease
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Lancet
Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L
doi: 10.1016/S0140-6736(21)00666-8
RECOMMENDED
Inflammatory Bowel Disease
Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Kotwani P, Terdiman J, Lewin S
doi: 10.1093/ecco-jcc/jjaa018.
Inflammatory Bowel Disease
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis: Ustekinumab PK and exposure-response in UC
Clin Gastroenterol Hepatol.
Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ
doi: 10.1016/j.cgh.2019.11.059.
Inflammatory Bowel Disease
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis
J Crohns Colitis
Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V
doi: 10.1093/ecco-jcc/jjab135
Inflammatory Bowel Disease
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Inflamm Bowel Dis.
Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T
doi: 10.1093/ibd/izy304.
Inflammatory Bowel Disease
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Am J Gastroenterol.
Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Casteele NV, Pai RK, Feagan BG, Sandborn WJ, Jairath V
doi: 10.14309/ajg.
Inflammatory Bowel Disease
Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients
J Crohns Colitis.
Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN
doi: 10.1093/ecco-jcc/jjy064.